Nektar Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Nektar Therapeutics has a total shareholder equity of $131.0M and total debt of $112.6M, which brings its debt-to-equity ratio to 86%. Its total assets and total liabilities are $398.0M and $267.0M respectively.
Key information
86.0%
Debt to equity ratio
US$112.63m
Debt
| Interest coverage ratio | n/a |
| Cash | US$303.62m |
| Equity | US$130.99m |
| Total liabilities | US$267.05m |
| Total assets | US$398.03m |
Recent financial health updates
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Apr 24Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24Recent updates
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise
Feb 15Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry
Dec 31Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Nov 06Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Apr 24Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Aug 19Nektar: Time To Abandon Ship
Jul 17Nektar promotes internal executive to CFO role
Jul 01We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
May 11After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline
Apr 04Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts
Mar 09Nektar Therapeutics: Beaten Down By 2020
Jan 26We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth
Jan 13Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%
Dec 09Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business
Oct 05Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks
Sep 29Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration
Sep 23Financial Position Analysis
Short Term Liabilities: NKTR's short term assets ($330.7M) exceed its short term liabilities ($51.3M).
Long Term Liabilities: NKTR's short term assets ($330.7M) exceed its long term liabilities ($215.8M).
Debt to Equity History and Analysis
Debt Level: NKTR has more cash than its total debt.
Reducing Debt: NKTR's debt to equity ratio has increased from 19.2% to 86% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NKTR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NKTR has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 31.9% each year.